2400 healthy volunteers get scanned to spot silent disease early
NCT ID NCT06906042
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time
Summary
This study will use MRI and ultrasound to create detailed reference images of the heart, liver, and blood vessels in 2,400 healthy adults across France. By linking these images with health data, researchers hope to better understand normal aging versus disease, especially for conditions like heart and liver disease that often have no early symptoms. The goal is to improve early detection and prevention for everyone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better understand what healthy hearts and livers look like, leading to earlier detection of disease.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly change medical practice, and results depend on the diversity of the volunteer group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Mar 2033
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Study participants are asymptomatic volunteers from the Constances cohort, whose risk factor profiles are representative of the population in the Île-de-France region (Paris area). Participants are divided into 6 decades from 20 to 80 years with equal distribution of men/women (200 men and 200 women per decade)
- Ages
-
20 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participation to the Constances cohort * Age ≥ 20 years * No overt cardiovascular or hepatic disease or related symptoms * No known family or personal genetic disease * Affiliation with a social security scheme or beneficiary of such a scheme. * Agreement to sign the consent Exclusion Criteria: * Renal function impairment with GFR \< 60 mL/min/1.73m2 * Deprived of liberty or persons subject to a legal protection measure (under guardianship or trusteeship) * People with contraindications to MRI (claustrophobia, presence of metallic elements…) * Pregnant or breastfeeding woman (pregnancy urinary test before inclusion for women of childbearing age).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Pitié-Salpêtrière
RECRUITINGParis, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe the nerve highways behind strength gains
- New syphilis test kits put to the test with donated blood
- Can a copy of a blockbuster arthritis drug match the original? scientists test it in healthy people
- Novo nordisk tests Brand-New molecule in humans for the first time
- New sedative candidate goes Head-to-Head with propofol in early human test
- Can a Room-Temperature dairy drink build muscle?